Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 10.

Noguchi, T; Kato, T; Wang, L; Maeda, Y; Ikeda, H; Sato, E; Knuth, A; Gnjatic, S; Ritter, G; Sakaguchi, S; Old, L J; Shiku, H; Nishikawa, H (2012). Intracellular tumor-associated antigens represent effective targets for passive immunotherapy. Cancer Research, 72(7):1672-1682.

Karbach, J; Neumann, A; Atmaca, A; Wahle, C; Brand, K; von Boehmer, L; Knuth, A; Bender, A; Ritter, G; Old, L J; Jäger, E (2011). Efficient in vivo priming by vaccination with recombinant NY-ESO-1 protein and CpG in antigen naive prostate cancer patients. Clinical Cancer Research, 17(4):861-870.

Burckhart, T; Thiel, M A; Nishikawa, H; Wüest, T; Müller, D; Zippelius, A; Ritter, G; Old, L; Shiku, H; Renner, C (2010). Tumor-specific crosslinking of GITR as costimulation for immunotherapy. Journal of Immunotherapy, 33(9):925-934.

Bauer, S; Oosterwijk-Wakka, J C; Adrian, N; Oosterwijk, E; Fischer, E; Wüest, T; Stenner, F; Perani, A; Cohen, L S; Knuth, A; Divgi, C; Jäger, D; Scott, A M; Ritter, G; Old, L J; Renner, C (2009). Targeted therapy of renal cell carcinoma: synergistic activity of cG250-TNF and IFNg. International Journal of Cancer, 125(1):115-123.

Bauer, S; Adrian, N; Siebenborn, U; Fadle, N; Plesko, M; Fischer, E; Wüest, T; Stenner, F; Mertens, J C; Knuth, A; Ritter, G; Old, L J; Renner, C (2009). Sequential cancer immunotherapy: targeted activity of dimeric TNF and IL-8. Cancer Immunity, 9(2):1-10.

Guggenheimer, D; Hasler, U; Krauer, R; Sonderegger, S (2009). Medizinische Fürsorge in der Stadt St. Gallen: mittelalterliche und frühneuzeitliche Dokumente aus dem Stadtarchiv St. Gallen. Zürich: Chronos Verlag.

Jäger, E; Gnjatic, S; Nagata, Y; Stockert, E; Jäger, D; Karbach, J; Neumann, A; Rieckenberg, J; Chen, Y T; Ritter, G; Hoffman, E; Arand, M; Old, L J; Knuth, A (2000). Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. Proceedings of the National Academy of Sciences of the United States of America, 97(22):12198-12203.

Jäger, E; Nagata, Y; Gnjatic, S; Wada, H; Stockert, E; Karbach, J; Dunbar, P R; Lee, S Y; Jungbluth, A; Jäger, D; Arand, M; Ritter, G; Cerundolo, V; Dupont, B; Chen, Y T; Old, L J; Knuth, A (2000). Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. Proceedings of the National Academy of Sciences of the United States of America, 97(9):4760-4765.

Jäger, E; Jäger, D; Karbach, J; Chen, Y T; Ritter, G; Nagata, Y; Gnjatic, S; Stockert, E; Arand, M; Old, L J; Knuth, A (2000). Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101-0103 and recognized by CD4(+) T lymphocytes of patients with NY-ESO-1-expressing melanoma. Journal of Experimental Medicine, 191(4):625-630.

Jäger, E; Stockert, E; Zidianakis, Z; Chen, Y T; Karbach, J; Jäger, D; Arand, M; Ritter, G; Old, L J; Knuth, A (1999). Humoral immune responses of cancer patients against "Cancer-Testis" antigen NY-ESO-1: correlation with clinical events. International Journal of Cancer, 84(5):506-510.

This list was generated on Sun Sep 24 12:30:19 2017 CEST.